BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/30/2021 8:21:53 AM | Browse: 319 | Download: 334
 |
Received |
|
2021-03-11 03:27 |
|
Peer-Review Started |
|
2021-03-11 03:31 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-05-11 20:46 |
|
Revised |
|
2021-05-20 01:29 |
|
Second Decision |
|
2021-07-12 03:32 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-07-12 06:00 |
|
Articles in Press |
|
2021-07-12 06:00 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-11-28 13:52 |
|
Typeset the Manuscript |
|
2021-12-26 15:00 |
|
Publish the Manuscript Online |
|
2021-12-30 08:21 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Case Report |
| Article Title |
Successful response to camrelizumab in metastatic bladder cancer: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Chen Xie, Xia Yuan, Shu-Hui Chen, Zhi-Yong Liu, Di-La Lu, Feng Xu, Zhi-Qiu Chen and Xiao-Ming Zhong |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xiao-Ming Zhong, PhD, Chief Doctor, Department of Radiology, Jiangxi Provincial Tumour Hospital, No. 519 Beijing East Road, Nanchang 330029, Jiangxi Province, China. jddxf2012@126.com |
| Key Words |
Programmed death-ligand 1; Tumor mutational burden; Bladder cancer; Camrelizumab; Next-generation sequencing; Case report |
| Core Tip |
Eighty percent of patients with positive programmed death-ligand 1 (PD-L1) are unable to benefit from immunotherapy. Herein, we report a case of a 74-year-old male patient with recurrent metastatic bladder cancer, which demonstrated positive PD-L1 expression and high tumor mutational burden. Immune checkpoint inhibitor camrelizumab was administered to the patient in combination with gemcitabine and cisplatin. The patient achieved a partial response with progression-free survival of 11 mo. More effective predictors of bladder cancer immunotherapy have yet to be explored, and the combination of multiple factors may be more predictive than a single factor. |
| Publish Date |
2021-12-30 08:21 |
| Citation |
Xie C, Yuan X, Chen SH, Liu ZY, Lu DL, Xu F, Chen ZQ, Zhong XM. Successful response to camrelizumab in metastatic bladder cancer: A case report. World J Clin Cases 2022; 10(1): 254-259 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i1/254.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i1.254 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
